

is May 5, 1995. Please note that this is a departure from the traditional approach of using postmarks instead of receipt date to determine eligibility of applications for review.

ADDRESSES: Application receipt: Department of Health and Human Services, ACF Division of Discretionary Grants, 370 L'Enfant Promenade, S.W., Washington, D.C. 20447. Attn: ACF-93588.951-A.

FOR FURTHER INFORMATION ON THE COMMUNITY SCHOOLS PROGRAM CONTACT: Department of Health and Human Services, AC/ACYF, Family and Youth Services Bureau, P.O. Box 1182, Washington, D.C. 20013. Telephone (202) 205-8076. Information is also available on the ACF Electronic Bulletin Board. To access, set modem to No Parity, 8 Data Bits, 1 Stop Bit and dial 1-800-627-8886. Under "Program Office Subsystems, Family and Youth Services Bureau," relevant files are found under COMMSCH.

FOR FURTHER INFORMATION ON THE FACES PROGRAM CONTACT: Department of Education, OESE, Safe and Drug Free Schools Program, 600 Independence Avenue, S.W., Washington, D.C. 20202. Telephone (202) 260-3954.

Catalog of Federal Domestic Assistance Number 84.285A for the FACES Program and Number 93.588 for the Community School Program.)

Dated: March 7, 1995.

Olivia A. Golden,

Commissioner, Administration on Children, Youth and Families.

[FR Doc. 95-6252 Filed 3-13-95; 8:45 am]

BILLING CODE 4184-01-P

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Cooperative Agreements for National/Regional Minority Organization Human Immunodeficiency Virus (HIV)/Sexually Transmitted Diseases (STD) Prevention, Immunization, and Tuberculosis (TB) Projects-Program Announcement 305b: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: Disease, Disability, and Injury Prevention and Control SEP: Cooperative Agreements for National/Regional Minority Organization HIV/STD Prevention, Immunization, and TB Projects-Program Announcement 305b.

Time and Date: 8:30 a.m.-4:30 p.m., April 18, 1995.

Place: Corporate Square, Building 11, Room 2320, Corporate Square Boulevard, Atlanta, Georgia 30329.

Status: Closed.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcement 305b. The applications being reviewed include information of a confidential nature, including personal information concerning individuals associated with the applications.

The meeting will be closed to the public in accordance with provisions set forth in section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Public Law 92-463.

Contact Person for More Information: John R. Lehnerr, Chief, Resource Analysis Office (E07), National Center for Prevention Services, CDC, Corporate Square, Corporate Square Boulevard, Atlanta, Georgia 30329, telephone 404/639-8023.

Dated: March 7, 1995.

Arthur C. Jackson,

Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95-6236 Filed 3-13-95; 8:45 am]

BILLING CODE 4163-18-M

Food and Drug Administration

Comparing Treatments: Safety, Effectiveness, and Cost-Effectiveness; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that it is holding a meeting to explore methodological and regulatory issues in the design and review of studies intended to show differences or similarities among active drug and biological therapies. As the pharmaceutical marketplace evolves, there are new pressures on the developers of drug/biological products to demonstrate comparative effects. This meeting will examine the needs for this type of information, how the pharmaceutical industry is responding to new demands for comparative information, case-study experience ruling out biases in study design, the use of observational studies, methodological concerns in effectiveness trials, and promotional considerations. The study will examine issues concerning evaluation of safety, effectiveness, and cost-effectiveness.

DATES: The meeting will be held on Thursday, March 23, 1995, 8 a.m. to

5:30 p.m., and on Friday, March 24, 1995, 8:30 a.m. to 5 p.m.

ADDRESSES: The meeting will be held at the National Institutes of Health, Clinical Center, Bldg. 10, Jack Masur Auditorium, 9000 Rockville Pike, Bethesda, MD. Copies of the transcript of the meeting will be available from the contact person listed below. There is no registration fee for this meeting. Interested persons are encouraged to register early because space is limited.

FOR FURTHER INFORMATION CONTACT: Regarding information concerning the meeting and registration forms: Louis A. Morris, Center for Drug Evaluation and Research (HFD-240), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-6812, FAX 301-594-6759.

Dated: March 8, 1995.

William B. Schultz,

Deputy Commissioner for Policy.

[FR Doc. 95-6199 Filed 3-13-95; 8:45 am]

BILLING CODE 4160-01-F

Health Resources and Services Administration

Rural Regional Trauma and Emergency Medical Services System Demonstration Grant Project in South Central Florida

AGENCY: Health Resources and Services Administration, Public Health Service, Department of Health and Human Services.

ACTION: Notice of extension of application due date.

SUMMARY: This notice extends the application due date for a Rural Regional Trauma and Emergency Medical Services (EMS) Demonstration Grant Project in South Central Florida. The application due date for the South Central Florida project is extended to May 15, 1995. All other aspects of the February 15, 1995 Federal Register Notice remain the same.

Dated: March 9, 1995.

Ciro V. Sumaya,

Administrator.

[FR Doc. 95-6198 Filed 3-13-95; 8:45 am]

BILLING CODE 4160-15-M

National Institutes of Health

National Institute of General Medical Sciences; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting: